Project Details
Description
ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy in Children with Newly Diagnosed High-Risk NBL
| Status | Active |
|---|---|
| Effective start/end date | 1/1/22 → 12/31/24 |
Funding
- PUBLIC HEALTH INSTITUTE
- PFIZER, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.